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SUMMARY 
 
 
Introduction: Portal hypertension is the hemodynamic consequence of 
cirrhosis.  It is considered a milestone in the progression of chronic liver 
disease preluding the onset of the most important complications. 
Elastography is rapidly gaining ground as a non-invasive tool for the 
diagnosis and characterisation of PH.  
Aims: 1. To compare liver stiffness measured by vibration-controlled 
transient elastography (Fibroscan) with liver stiffness measured by point 
shear wave elastography (ElastPQ) and evaluate their correlation. 2. To 
evaluate the diagnostic accuracy of ElastPQ in detecting clinically 
significant portal hypertension by comparing liver and spleen stiffness with 
hepatic venous pressure gradient  in  a  population of patients with chronic 
liver disease. 3. To evaluate the correlation of liver stiffness with liver 
fibrosis in a subgroup of patients who underwent hepatic venous pressure 
gradient measurement and liver biopsy.  4. To evaluate the accuracy of liver 
and spleen stiffness in discriminating cirrhotic portal hypertension from 
non-cirrhotic portal hypertension.  
Patients and Methods: 78 patients with chronic liver disease attending 
the Royal Free Hospital who underwent hepatic venous pressure gradient 
measurements for clinical purposes were recruited in the study.  Only 70 
were enrolled because in 8 there were technical limitations and spleen 
stiffness could not be measured. The population was heterogeneous in 
terms of age (59 ± 11), gender (M 78%, F 22%) and aetiology (HCV 17.1%, 
4 
 
HBV 8.6%, NASH 31.4%, ALD 5.7%, other 37.2%). Elastography was 
measured with ElastPQ (Affiniti 70 G Philips Healthcare) just before the 
hemodynamic assessment in all 70 participants, and also with vibration-
controlled transient elastography (Fibroscan, Echosens, Paris) in a 
subgroup of 41 patients.  Liver stiffness with ElastPQ (13.8), spleen stifness 
with ElastPQ (40.1), spleen size (13), platelet count (181) and LSPS [liver 
stiffness*(Spleen diameter/platelet count)] (1.2), were correlated to 
hepatic venous pressure gradient.  Another subgroup of 45 patients had a 
histopathological sample obtained by transjugular approach at the time of 
hepatic venous pressure gradient measurement, within 3 months prior to 
the assessment by percutaneous biopsy or obtained from the resected liver 
of those patients who underwent surgery for hepatocellular carcinoma. In 
order to have an objective evaluation of the amount of fibrosis, collagen 
proportionate area was calculated for every histopathological sample and 
expressed as percentage related to the area of collagen. Collagen 
proportionate area was then correlated first with hepatic venous pressure 
gradient measurement and then with both liver and spleen stiffness 
measured by ElastPQ.  Finally, in order to evaluate the diagnostic accuracy 
of ElastPQ in characterising portal hypertension, we compared the 
subgroup of cirrhotic patients affected by clinically significant portal 
hypertension (26) with a group of patients with non-cirrhotic portal 
hypertension (21) due to extra-hepatic portal vein obstruction secondary 
to myeloproliferative neoplasm. Liver stiffness, spleen stiffness, spleen size, 
spleen stiffness/liver stiffness ratio and platelet count were used as 
parameters for comparison.  
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Results: 45 patients underwent both ElastPQ and fibroscan measurements. 
An excellent correlation between the two techniques was found 
(Spearman’s 0.941, p<0.0001). 26/70 patients (37.2%) had clinically 
significant portal hypertension (HVPG ≥10 mmHg).  Liver stiffness 
(ElastPQ) (p<0.0001), spleen stiffness (ElastPQ) (p<0.0001), spleen size 
(p<0.001), platelet count (p<0.0001) and LSPS (p<0.0001) all correlated 
significantly with clinically significant portal hypertension. However, on 
multivariate analysis, spleen stiffness was the only parameter 
independently correlated with clinically significant portal hypertension 
(OR 1.099, 95% CI 1.017 – 1.188, p<0.017). The spleen stiffness AUROC for 
HVPG≥10 mmHg was 0.918, p<0.0001, cut off value 42.7 kPa, sensitivity 
96%, specificity 84%, negative predictive value 97.4% and positive 
predictive value 78.1%. Collagen proportionate area was found to have an 
excellent correlation with hepatic venous pressure gradient (p<0.0001) 
and was also significantly correlated to liver stiffness measured with 
ElastPQ (p<0.0001) and spleen stiffness (p<0.005). Finally liver stiffness 
(p<0.0001), spleen stiffness (p<0.0001), platelet count (p<0.009) spleen 
size (p<0.001) and spleen stiffness/liver stiffness ratio (p<0.0001) were 
able to discriminate CPH from NCPH.  
Conclusions:  In this population of patients ElastPQ was found to have an 
excellent correlation with Fibroscan which so far has been considered the 
gold standard of reference for non-invasive measurement of liver fibrosis 
and portal hypertension. Liver and especially spleen stiffness measured by 
ElastPQ correlated significantly with hepatic venous pressure gradient 
being able to discriminate clinically significant portal hypertension from 
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non-clinically significant portal hypertension with high accuracy. Both liver 
stiffness and spleen stiffness correlated well with collagen proportionate 
area which is a true quantitative measurement of liver fibrosis that also 
correlates faithfully with portal hypertension. Finally it was shown that 
ElastPQ is particularly useful for distinguishing cirrhotic portal 
hypertension from non-cirrhotic portal hypertension and overall should be 
considered as a rapid, accurate and non-invasive method, valuable for 
assessing liver disease in its multifaceted clinical presentations.  
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1.  INTRODUCTION 
 
 
Chronic liver disease is an inflammatory disorder that may progress to 
fibrosis and cirrhosis if the pathogenic noxae is not withdrawn. The 
underlying aetiology has surely a role in the pattern of inflammation, 
distribution of fibrosis and therefore the natural history of liver disease. 
The histopathological characteristics remain one of the reasons for which 
liver biopsy cannot and should not be replaced by other methods. 
Nevertheless non-invasive assessment is based on ultrasound techniques 
able to describe the liver and spleen appearance as well as the vascular 
anatomy and flow of the splanchnic circulation. In addition, this 
“subjective” description can now be integrated by measuring a 
biomechanical parameter such as tissue stiffness, the use of which is 
overcoming liver biopsy for staging and follow up purposes. Portal 
hypertension (PH) represents the hemodynamic consequence of cirrhosis, 
it is considered a milestone in the progression of liver disease and preludes 
the onset of the most important complications. Therefore, the management 
of patients with liver disease relies on prognostic stratification, which is 
mainly relative to PH. It is within the clinical frame of diagnosis, follow up 
and staging that the importance of non-invasive assessment is more and 
more recognised by the hepatology community.  
ElastPQ is a fairly new point shear wave elastography (pSWE) technique 
that has not yet been validated for the assessment of PH. This study aims to 
establish the correlation between liver stiffness (LS) measured by ElastPQ 
and vibration-controlled transient elastography (VCTE) in patients who 
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underwent HVPG measurement for clinical purposes; to evaluate the 
correlation of ElastPQ in detecting and grading PH by measuring LS and 
spleen stiffness (SS) in a population of patients with chronic liver disease 
who underwent haemodynamic assessment; to investigate the correlation 
between LS measured by ElastPQ and liver fibrosis measured by collagen 
proportionate area (CPA).  Ultimately PH will be classified by comparing LS 
and SS values measured in a subgroup of patients with cirrhotic CSPH 
(HVPG ≥ 10 mmHg) and another group of patients with extra-hepatic portal 
venous obstruction (EHPVO) who were known to have CSPH because of the 
presence of portal-systemic collateral vessels on cross sectional imaging. 
 
2. DEFINITION AND CLASSIFICATION OF PH 
PH is a clinical syndrome characterised by the presence of increased 
resistance to blood flow in the portal venous system and/or its tributaries 
(spleno-mesenteric-portal venous axis).  According to the site of resistance 
PH is classified in pre-hepatic, intra-hepatic (pre-sinusoidal, sinusoidal and 
post-sinusoidal) and post-hepatic (Figure 1). Pre-hepatic portal 
hypertension is mainly due to EHPVO, usually caused by thrombosis. In the 
majority of cases liver parenchyma is not affected although there might be 
signs of arterialisation since a longstanding reduced portal inflow may 
induce hypertrophy of the hepatic artery and further arterial angiogenesis. 
A typical feature of EHPVO is the presence of portal vein cavernoma, which 
is the result of the attempt to re-canalize and bypass the thrombosed portal 
vein. The spleen is typically enlarged and other portal-systemic vascular 
collaterals might also be present.  Among the intrahepatic causes, cirrhosis 
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is the most frequent condition, while idiopathic portal hypertension (IPH) 
and EHPVO account for less than 10%. IPH is typically characterised by 
splenomegaly, none or mild hepatic fibrosis and the presence of portal-
systemic collaterals as a consequence of PH. The liver’s heterogeneous 
echotexture and often abnormal shape may be initially misleading 
suggesting the presence of cirrhosis which however is excluded by the 
histological and hemodynamic picture. Intrahepatic causes can be further 
classified as pre-sinusoidal, sinusoidal or post-sinusoidal according to the 
site of intrahepatic resistance. Pre-sinusoidal portal hypertension is 
characterized by increased resistance in the peri-portal areas and can be 
caused by schistosomiasis, nodular regenerative hyperplasia, primary 
biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), sarcoidosis. 
Nevertheless in advanced stages the sinusoidal tracts also may be involved. 
Post-hepatic portal hypertension is instead associated to venous outflow 
obstruction which is typically secondary to Budd-Chiari syndrome or to 
right heart impairment. 
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Fig 1. Schematic illustration from the “Sheila Sherlock Book of Hepatology” showing the 
pathophysiological classification of portal hypertension. 
 
 
3. PATHOPHYSIOLOGY OF PH 
PH in cirrhosis develops as a consequence of structural changes of liver 
parenchyma due to inflammation, collagen deposition, nodule formation 
and vascular occlusion/remodelling. This “static” component causes the 
initial vascular modifications responsible for increasing portal pressure. 
Nevertheless about 1/3 of PH is caused by a functional “dynamic” 
component [1] which is used by the activation of stellate cells with active 
contraction of myofibroblasts and vascular smooth muscle cells in portal 
venules [2]. This in turn is caused by increased endogenous 
vasoconstrictors, such as endothelin, and reduced nitric oxide 
bioavailability [3-4]. Porto-systemic collaterals develop as a consequence 
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of the high pressure in the portal vein and ameliorate the increased 
resistance. However, even when portal blood flow is entirely diverted 
through collaterals, PH persists because of a concomitant increase in portal 
venous inflow, which in turn is caused by splanchnic vasodilatation, [5] 
mostly mediated by an increase in nitric oxide. The most important 
collaterals are those that constitute gastroesophageal varices. Although the 
formation of collaterals had been assumed to be the result of dilatation of 
pre-existing vascular channels, recent studies have implicated a process of 
neoangiogenesis. This process has been shown to contribute not only to 
portal-systemic collaterals but also to the formation of a new arteriolar-
capillary network through angiogenesis [6]. While the “static” component 
increases due to progressive collagen deposition and nodular regeneration, 
the “dynamic” component increases progressively intrahepatic resistances, 
splanchnic vasodilation and inflow that is diverted through portal-systemic 
collaterals. This results in further recruitment of vascular shunts, 
splenomegaly and further systemic increase of vasodilators which 
ultimately leads to a mismatch of vascular resistances and redistribution of 
blood volume. The neuro-hormonal modifications, triggered mainly by 
renal hypoperfusion, maintain the vicious cycle and actively contribute to 
the pathogenesis of hyperdynamic circulation that is the consequence and 
cause of further establishment of haemodynamic abnormalities that 
characterize cirrhosis in its most advanced stages. 
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4. NATURAL HISTORY 
The relevance of PH derives from the frequency and severity of its 
complications, which represent the first cause of hospitalisation, liver 
transplantation and death. These complications include the formation of 
oesophageal or gastric varices, variceal bleeding, ascites, spontaneous 
bacterial peritonitis, hepatorenal syndrome, portopulmonary hypertension, 
hepatic encephalopathy, portal hypertensive gastropathy, enteropathy and 
altered metabolism of endo and xenobiotics normally metabolised by the 
liver [7].  
All patients with cirrhosis will eventually develop PH and gastroesophageal 
varices. Bleeding from ruptured varices is the most threatening 
complication of cirrhosis and is the cause of death in about one third of 
patients. The rate of development and growth of oesophageal varices is 
poorly defined but in general seems to be related to the degree of liver 
dysfunction. Once varices have formed, they tend to increase in size and 
eventually to bleed. Variceal size is the single most important predictor of a 
first variceal bleeding episode. The risk of hemorrhage is greatest in the 
first days following a bleeding episode and slowly declines thereafter. 
Varices can also be found in the stomach of cirrhotic patients, alone or in 
association with esophageal varices. Gastric varices bleed less frequently 
but more severely than esophageal varices. Portal hypertensive 
gastropathy is a common feature of cirrhosis, and its prevalence parallels 
the severity of PH and liver dysfunction. Portal hypertensive gastropathy 
can progress from mild to severe and vice-versa or even disappear 
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completely. Acute bleeding from portal hypertensive gastropathy seems to 
be relatively uncommon, and less severe than bleeding from varices [8]. 
The differences between CPH and NCPH are not only topographical and 
pathophysiological; there is also a huge difference in terms of natural 
history and prognosis. While NCPH includes a variety of different 
pathologies and is often an occasional finding in the context of an 
underlying condition, PH in cirrhosis has a clear role and is used for 
prognostic stratification. Moreover while in NCPH the liver might be 
healthy, in cirrhosis it is obviously severely affected and a bleeding episode 
has an increased risk of hepatic decompensation and death. 
 
 
5. DIAGNOSIS OF PH 
 
5.1 CLINICAL PRESENTATION 
Chronic liver disease usually progresses in an indolent manner until 
complications, in general secondary to CSPH, do not occur. Ascites, pitting 
edema, palmar erythema, spider naevi, gynecomastia, abdominal wall 
collateral circulation, splenomegaly are all signs of advanced cirrhosis. 
However chronic liver disease typically does not declare itself when portal 
hypertension is within the subclinical range of 6-9 mmHg and sometimes 
even if the HVPG threshold of CSPH is reached (>10 mmHg). Nevertheless, 
after this stage is reached, signs and symptoms may present gradually or as 
a dramatic event such as variceal bleeding.  Hence while a positive clinical 
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examination is highly specific, a negative one may hide the presence of 
cirrhosis. In conclusion in a patient with a medical history of chronic liver 
disease, a negative physical examination has poor diagnostic accuracy and 
cannot be trusted. Its usefulness is instead relevant when CSPH leads to 
known stigmata of cirrhosis (ascites, palmar erythema, splenomegaly, 
spider naevi). 
 
5.2 SEROLOGY  
Several serum markers have shown to be able to reflect the underlying 
changes of hepatic dysfunction, fibrosis, cirrhosis and PH. Some of these 
markers are non-specific tests (indirect or surrogate markers), which 
combined together increase their accuracy in predicting fibrosis and 
related PH. Among these surrogate markers the AST to platelet ratio score 
(APRI) and the Fibrotest are used in clinical practice. The FibroTest, which 
is a combination of α2-macroglobulin, ApoA1, Bilirubin, γGT, haptoglobin 
measurements, is the most validated indirect test for liver fibrosis [9-11]. 
Nevertheless, although these markers have shown a good correlation with 
advanced stages of liver disease they have not been proved useful in 
distinguishing different stages of fibrosis, resulting inadequate tests for 
monitoring the progression of liver disease. As for PH, Child-Pugh score 
and its objective component (albumin, bilirubin, INR) correlate with HVPG 
[11-14] and with the prevalence and grade of esophageal varices in 
cirrhotic patients. Interestingly this correlation is observed also in patients 
with compensated cirrhosis [15], suggesting that a close relationship exists 
between the structural changes that give onset to PH and hepatocellular 
17 
 
dysfunction. Platelet count is independently correlated with the prevalence 
and grade of esophageal varices in several studies [16-17] and platelet 
count to spleen diameter ratio >909 has been shown to have a 100% 
negative predictive value for the presence of esophageal varices [18] 
suggesting that it could be of help in avoiding unnecessary endoscopies. A 
second panel is represented by direct markers that reflect the constituents 
of the extracellular matrix released in the blood stream as a consequence of 
the remodeling process (fibrogenesis and fibrinolysis) [19].  The enhanced 
liver fibrosis (ELF) score is a combination of hyaluronic acid, tissue 
inhibitor of matrix metalloproteinases-1 and aminoterminal propeptide of 
type III procollagen, all of which have shown good accuracy in being able to 
distinguish different stages of fibrosis and in particular advanced fibrosis 
and cirrhosis [20]. Lately a recent study has shown how the results may 
vary also according to sex, age, BMI and therefore these differences should 
be considered when interpreting ELF test [21]. Guechot and colleagues 
looked at the predictive value of hyaluronic acid in a series of patients with 
HCV cirrhosis, followed up for a median of 38 months [22]. In this study, 
hyaluronic acid had a predictive value equivalent to Child-Pugh score for 
the prediction of severe complications of cirrhosis or death and therefore 
for the severity of PH. Several serological markers have been proposed for 
the detection of CSPH including [23] a score combining total bilirubin and 
platelet count and Fibrotest [23-25]. Similarly other biological markers 
were used to study the correlation with the presence of oesophageal 
varices.  Of these the Lok and Forns index showed the best predictive value 
[26]. 
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5.3 ENDOSCOPY 
Variceal bleeding is the most life-threatening complication of cirrhosis. 
Hence once the diagnosis of cirrhosis is made, gastroscopy is the primary 
investigation because of its sensitivity, specificity and potential therapeutic 
approach. There are two moments in the follow-up of patients with chronic 
liver disease in which endoscopy is absolutely crucial: at the time of 
diagnosis of cirrhosis and once varices are detected, since the grade and 
risk of bleeding (defined by the size and presence of wale marks and red 
spots) influence the kind of endoscopic approach which will be eradication 
or follow-up. Nevertheless, endoscopy is an expensive and uncomfortable 
procedure and knowing when is the best time to start screening a specific 
patient is very important. Non-invasive assessment by VCTE has provided 
useful insights and has recently been considered the standard of reference 
in adjunction to platelet count to decide when cirrhosis is complicated by 
CSPH and is therefore likely associated to the development of 
gastroesophageal varices (Baveno VI Consensus Conference), giving 
indication when patients should undergo variceal screening and when they 
could safely avoid it. However, this evaluation was carried out mainly in 
patients with viral-related cirrhosis and this is not representative of the 
whole spectrum of liver disease. Moreover it is important to highlight that 
endoscopy does not diagnose PH but it describes its expression in the most 
frequent and dangerous anatomical site of vascular collateral circulation 
development.  In a minority of cases patients will develop ectopic varices 
which could be located at the level of the duodenum or even in the small 
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bowel with an equally threatening significant risk of bleeding. 
Alternatively, in the presence of cirrhosis with suspected CSPH and a 
negative endoscopic evaluation, the presence of vascular shunting with 
decongestion of the portal venous system should always be borne in mind.  
 
 
5.4 HAEMODYNAMIC ASSESSMENT 
Haemodynamic assessment of PH sees its origins more than 60 years ago. 
Initially portal pressure was measured by direct puncture of the portal 
vein. However this was invasive and inconvenient and carried a significant 
risk of complications.  In 1951, Myers and Taylor first described wedge 
hepatic venous pressure (WHVP), which is the measurement of the 
sinusoidal pressure obtained by occlusive hepatic vein catheterisation, an 
indirect measurement of portal venous pressure (PVP) [27]. In 1954 
Atkinson and Sherlock carried out a pioneering study to measure and 
characterise PH in patients with cirrhosis and EHPVO [Fig 2] [28]. The 
rationale was based on the fact that the splenic red pulp is in direct 
communication with the splenic portal free radicals which drain in the 
portal venous system, hence the presence of PH would be transmitted and 
therefore measurable through the spleen. “Patients were placed recumbent 
with their left arm behind their head. A site was chosen in either the 8th or 
9th intercostal space in the mid-axillary line. After injecting local 
anaesthetic a fine 7 cm lumbar puncture needle was introduced 2 cm into 
the spleen and the needle was connected to a pressure system. 
Contemporarily, a WHVP was carried out to evaluate the difference of 
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hepatic contribution”. While intrasplenic pressure was raised in both 
cohorts of patients with PH with no signficant difference between the two 
groups, the WHVP instead showed a considerable difference being able to 
clearly distinguish patients with CPH from those with NCPH. In 1957 a 
similar but more extensive study was carried out by Turner et al to further 
corroborate the previous results and investigate the clinical applications of 
these techniques [29]. The study was carried out on a population of 109 
subjects composed by patients with cirrhosis, NCPH and splenomegaly of 
unknown cause. Percutaneous intrasplenic pressure, trans-splenic 
venography of the portal venous system and WHVP were measured for 
each participant. The authors first showed that intrasplenic pressure does 
not change if measured in different sites, meaning that portal pressure is 
homogeneously transmitted to the red pulp [Fig 3].  
 
Fig. 2. The drawing illustrates the technique used  for indwelling pressure measurements of 
both liver and spleen in a patient with portal hypertension due to extra-hepatic portal vein 
obstruction [28]. 
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Fig. 3 . The relationship between pressure recorded at two different sites in the same spleen  
[29]. 
 
The results showed also that, in general, vascular collaterals were 
associated to increased intrasplenic pressure as an expression of PH, and 
that intrasplenic pressure was high in the majority of patients who had a 
variceal bleed compared to those who did not. However, it was also shown 
that some patients with no collateral circulation had high intrasplenic 
pressure, while in some with very large vessles it was low [Fig 4]. “In one 
patient with cirrhosis the intrasplenic pressure fell spontanously from 25 
mmHg to 12 mmHg in twelve months. A venogram at the time of the second 
pressure measurement showed enormous oesophageal vessels which had 
presumably lowered portal hypertension”.  This result suggests that the 
splenic pressure is relieved by the presence of a natural or iatrogenic 
collateral vascular circulation as proven by measuring intrasplenic 
pressure in patients before and after undergoing a porto-caval shunt. In the 
latter scenario intrasplenic pressures were significantly lower after the 
procedure, while they remained high in the case of blockage or shunt 
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mulfunction [Fig 5]. Therefore splenic pressures could be used as a 
predictor of treatment response. In order to examine the relationship of 
various hemodynamic parameters, years later Sarin et al measured the 
correlation between WHVP, intrahepatic interstitial pressure, intrasplenic 
pressure and intravariceal pressure in patients with CPH and NCPH 
showing an excellent correlation between intrasplenic and intravariceal 
pressure in both populations. Hepatic pressures were instead significantly 
higher in the cirrhotic population compared to the other,  as expected [Fig 
6-8]. 
 
 
 
Fig 4. The correlation between the intrasplenic pressure and the presence or absence of 
vascular collaterals in cirrhotic patients [29]. 
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Fig 5 . Succesful porto-caval anastomosis is followed by a fall in intrasplenic pressure. 
Hatched area represents normal range of intrasplenic pressure. Readings were compared 
with venography result [29]. 
 
 
 
Fig 6. Intrasplenic and intravariceal pressure in patients with CPH and NCPH [29]. 
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Fig 7. Wedged hepatic pressure and intrasplenic pressure in CPH and NCPH (left). Wedge 
hepatic pressure and intravariceal pressure in CPH and in NCPH (right) [29]. 
 
 
Fig 8. Wedge hepatic pressure and intrahepatic pressure in CPH and NCPH [29]. 
 
Several subsequent studies showed similar correlations and served as 
further proof and validation of these methods. Nevertheless, splenic 
puncture and intravariceal puncture are particularly invasive and carry a 
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high risk of complications. However, the possibility of measuring variceal 
pressure was not abandoned, and in 1996 Nevens et al [30] measured 
variceal pressure with a specific device built in the endoscope. A subgroup 
of patients scheduled for variceal sclerotherapy also underwent 
intravariceal pressure measurement. A good correlation was found 
between the invasive and the non-invasive pressure measurements with 
the grade of varices and risk of bleeding expressed as red colour signs. 
While intrasplenic pressure measurement has been progressively 
abandoned, variceal pressure is still being investigated and increasingly 
refined technologies are being developed to non-invasively assess pressure 
within the varices and to monitor pharmachological response [31]. 
Although variceal pressure measurement is promising and was proposed 
recently by some authors as an alternative to other hemodynamic 
measurements, the gold standard for the measurement of PH remains 
HVPG, which is defined as the difference between the WHVP and the free 
hepatic venous pressure (FHVP). It is based on the concept that when the 
blood flow in a hepatic vein is blocked by a ‘wedged’ catheter, the static 
column of blood transmits the pressure from the preceding communicated 
vascular territory. In the normal liver, interconnected sinusoidal network 
partially dissipates the pressure backup from the wedged catheter, and the 
WHVP is slightly lower than directly-measured portal pressure. In cirrhosis 
the intersinusoidal communications are lost due to fibrosis, septa and 
nodule formation and the sinusoidal pressure equilibrates with portal 
pressure reliably [Fig 9]. Moreover, HVPG represents the gradient between 
the portal vein and the intra-abdominal vena caval pressure. In fact, portal 
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venous pressure or WHVP can be elevated falsely in the presence of ascites 
and elevated intra-abdominal pressure. Instead, since both the WHVP and 
FHVP are affected equally by intra-abdominal pressure, their gradient is 
not, reflecting faithfully possible increases in portal pressure. 
 
Fig 9. HVPG measurement in normal liver (A) and cirrhotic liver (B) [32]. 
 
5.4.1 Clinical Applications of HVPG  
HVPG is the gold standard for the measurement but also for the 
classification of PH. In patients with PH of unknown causes the finding of 
an increased HVPG owing to an increase in WHVP indicates an increase in 
sinusoidal pressure, which is most frequently due to cirrhosis. A normal 
HVPG with normal WHVP and FHVP is typical of presinusoidal portal 
hypertension such as schistosomiasis, early PBC, nodular regenerative 
hyperplasia [33]. Because the catheter in these cases is not in continuity 
with the area of increased resistance, the recorded pressure will be that of 
the normal sinusoids and not of the increased pressure in the portal vein 
underestimating portal pressure. In IPH the precise location of resistance 
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to portal venous flow is not exactly known. Two specific pathological 
lesions observed in this disease include occlusive changes  in the 
intrahepatic portal vein radicles which are focal in distribution and diffuse 
collagenisation of the space of Disse. Unless the fibrotic process does not 
extend to the sinusoids, PH is typically periportal and presinusoidal. Hence 
the wedge pressure is low in these patients [34-35].  In post-hepatic portal 
hypertension HVPG will be normal because both FHVP and WHVP will be 
increased. In addition HVPG measurement use has shown to go beyond 
diagnosis and classification. It has been extensively studied in the course of 
the natural history of cirrhosis, it is now recognised as the best surrogate 
marker of clinical events and is considered the best method for prognostic 
stratification of patients with CLD [36]. 
 
5.4.2 HVPG for staging chronic liver disease 
Once the cirrhotic stage is reached, chronic liver disease can be 
subclassified according to the presence or absence of vascular collateral 
circulation and clinical decompensation defined by the development of 
ascites, variceal hemorrhage, encephalopathy, and jaundice.  In general 
portal pressure is normal when HVPG is between 1 and 5 mmHg, not 
clinically significant between 6 and 9 mmHg, while the threshold of CSPH is 
instead defined by an HVPG ≥ 10 mmHg. Although this is generally 
considered the limit beyond which vascular collateral circulation develops, 
patients with an HVPG of 10 mmHg are rarely clinically symptomatic, are 
compensated and the mortality risk is low. Nevertheless it is also reported 
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that these patients do have a 22% risk of clinical decompensation at 2 
years [37] suggesting that prognosis starts to be heavely influenced once 
this threshold is reached. An HVPG ≥12 mmHg instead is classically 
associated with an increased risk of bleeding. Whether an increased 
mortality risk is observed when HVPG is above 16 mmHg [38-39] and 
during acute variceal bleeding a HVPG >20 mmHg (measured within 48 h of 
admission) predicts failure to control bleeding and low 1-year survival 
[40]. In patients with decompensated cirrhosis listed for liver 
transplantation HVPG holds prognostic value independent from that of 
model for end-stage liver disease (MELD) score [41]. Pre-operative portal 
pressure is an important predictor of hepatic decompensation in patients 
with cirrhosis after resection for HCC. Bruix et al evaluated that only HVPG 
was significantly associated with unresolved decompensation within 3 
months after surgery [42-43]. Therefore, preoperative HVPG  should be 
measured routinely in these patients [33]. Nevertheless, although HVPG is 
considered the gold standard for measuring portal pressure, it must be 
highlighted that the onset of CSPH and its related complications might be 
different according to the underlying aetiology and related pathopysiology 
as well as topographic distribution of fibrosis. Therefore, it should always 
be borne in mind that aetiologies which are associated to initial peri-portal 
fibrosis such as PBC or PSC may have an early onset of PH, that this is pre-
sinusoidal and hence it is associated to an underestimation of PH mesured 
by the HVPG. 
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5.5 IMAGING  
 
5.5.1 CT and MRI 
Computed tomographic scan (CT) and magnetic resonance (MRI) allow an 
accurate visualization of the liver parenchyma and the portal venous 
system. However, while single or multi-detector CT are reliable in detecting 
large esophageal varices (specificity 90–100% and sensitivity 84–100%), 
the sensitivity for small varices detection is lower [44]. Dynamic contrast-
enhanced single-section CT scans and MRI and phase contrast MR 
angiography allow a quantitative measurement of portal [45] and azygos 
[46] blood flow. Azygos blood flow correlates with the presence of 
esophageal varices at endoscopy, and with the risk of bleeding from 
varices. Portal fraction of liver perfusion and mean transit time at MRI, 
have been recently shown to have a good correlation with HVPG [47]. MRI 
has the advantage over CT of offering high contrast resolution without 
exposure to ionizing radiation or to large volumes of iodinated contrast 
media. In addition MRI elastography by synchronizing motion-sensitive 
imaging sequences with the application of acoustic waves in tissue media, 
is able to measure tissue response to an applied physical stress [48]. MRI 
elastography has been shown to be able to predict the stage of liver fibrosis 
in patients with chronic liver disease [49] and has been successfully 
applied to measure SS, which seems to have a closer correlation with portal 
pressure [50]. However, although MRI is a truly multi-parametric and 
excellent method to evaluate liver disease giving both qualitative and 
30 
 
quantitative information, it is very expensive, not available to every Centre 
and time consuming.  
 
 
5.5.2 Ultrasound 
Ultrasound is the first line examination used to assess and follow up liver 
disease including hepatocellular carcinoma screening. It is repeatable, not 
expensive and can be performed at the patient’s bedside. Moreover, with 
the latest technical advancements it truly has become a multi-parametric 
diagnostic tool. It can provide morphological information on liver 
appearance, on splanchnic blood flow (direction, velocities and impedance 
indexes), on tissue stiffness and, by using contrast enhanced software, it 
can provide fundamental information on the characterization of focal liver 
lesions as well as on parenchymal microperfusion. Therefore in expert 
hands it can surely give precious diagnostic and prognostic information on 
liver disease.  
The accuracy of ultrasound diagnostic performance is based on the 
combination of different sonographic signs [Table 1]. A basic gray scale 
analysis is important for the description of the parenchymal appearance. 
Size, shape, echo-texture and outline are the first findings to be described 
when assessing liver disease. Liver surface nodularity, although not 
exclusive, is one of the most specific signs of cirrhosis [51]. Nevertheless 
the sensitivity of single ultrasound findings is low. Interrogation of the liver 
vascular anatomy and spleen is extremely important and provides further 
information in order to increase ultrasound diagnostic accuracy. 
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Ultrasound signs of CSPH might be very specific, but their sensitivity is low 
especially in compensated cirrhosis; therefore, while the presence of a sign 
or a combination of signs definitely rules-in PH, its absence cannot exclude 
the diagnosis within certain limits (Table 1). When intrahepatic resistance 
is greater than the resistance of portal-systemic collaterals there is an 
inversion of portal blood which is 100% specific for PH, as well as the 
presence of portal-collateral circulation such as para-umbilical vein 
recanalization, spontaneous spleno-renal circulation, dilated left and short 
gastric veins [52]. Other ultrasound signs of CSPH include dilatation of 
portal vein (diameter >13 mm) [53]. Some authors have reported that a 
portal vein dilatation above 12 mm has a specificity of 95% for the 
diagnosis of PH in chronic liver disease, and has been consistently 
associated with esophageal varices. However in some cases portal venous 
caliber even in the presence of PH is normal. These differences may be 
related to the underlying cause of liver disease. Portal vein blood velocity 
can be assessed with good reproducibility. It usually decreases as portal 
pressure increases in cirrhosis as a consequence of the increased resistance 
to inflow. A maximum velocity below 16 cm/s and a mean below 12-10 
cm/sec should be considered strongly suggestive of CSPH [54]. The 
congestion index combines PV velocity and PV cross sectional area and has 
been related with the presence of esophageal varices [55]. Altered hepatic 
venous Doppler pattern [56], increased intra-parenchymal hepatic and 
splenic artery impedance [57–59], increased intra-parenchymal renal 
artery impedance [60] and reduced mesenteric artery impedance [61] are 
influenced by the presence of hyperdynamic circulation which is a 
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consequence of advanced cirrhosis. HVPG significantly correlates with 
some ultrasound parameters such as portal vein velocity and volume of 
blood flow [54], hepatic artery resistance index, splenic and renal artery 
resistance and pulsatility index. However the degree of correlation is only 
slight to moderate and these parameters cannot be used as reliable 
surrogates of HVPG [53]. Dilatation of splenic and mesenteric vein, and the 
reduction of the respiratory variations of their diameter are instead very 
specific signs of CSPH [61]. Ultrasound is highly sensitive in diagnosing 
ascites, which is the most common clinical decompensation event of 
cirrhosis and holds a severe prognostic significance [53]. Splenomegaly 
often accompanies the development of PH [62] in cirrhosis and is 
considered a physical stigmata of advanced chronic liver disease. In general 
it is thought to be associated with a more severe disease since it is more 
often observed in decompensated than compensated patients [63] as well 
as in patients with esophageal varices. As for the prediction of first clinical 
decompensation of any kind, spleen enlargement (>1 cm) on follow-up 
might be associated with a higher probability of developing the first clinical 
decompensation of cirrhosis [64]. However, spleen size sometimes may not 
correlate with the severity of PH even in case of advanced liver disease. 
This finding seems to be aetiology-related [65]. Ultrasound with color 
Doppler analysis is also particularly useful as a diagnostic guide for non-
cirrhotic causes of PH. In patients with no history of chronic liver disease 
but clinical signs of PH, particular attention should be payed to vessel 
patency. The presence of portal vein thrombosis and cavernomatous 
transformation is a pathognomonic sign of NCPH secondary to EHPVO. In 
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patients with no ultrasound signs of cirrhosis and patent portal and hepatic 
veins, the observation of signs of PH should suggest rare causes of PH such 
as arterial-portal fistulae, IPH or nodular regenerative hyperplasia [66]. 
Color Doppler ultrasound also permits an evaluation of the hepatic veins 
and the inferior cava vein, thus allowing the identification of possible post-
hepatic causes of PH, such as hepatic vein thrombosis (Budd-Chiari 
syndrome) in which caudate lobe hypertrophy can be very pronounced, 
with consequent compression of the retro-hepatic vena cava [67]. Right 
heart failure, tricuspid valve diseases and constrictive pericarditis can also 
induce PH and ultrasound Doppler is useful in outlining signs of increased 
central venous pressure such as dilatation of the inferior vena cava and the 
hepatic veins as well as the distortion of the spectral waveform. Ultrasound 
is also useful in the assessment of more complex and rarer causes of PH, 
such as sinusoidal obstruction syndrome and in patients with PH due to 
suspected hereditary hemorrhagic telangiectasia, in which an increased 
diameter of the common hepatic artery (>7mm), increased hepatic artery 
flow and the presence of intrahepatic hypervascularization and 
subcapsular vascular spots with a high-velocity arterial blood flow and low 
resistivity index, are highly sensitive and specific [68–70]. 
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5.6 ELASTOGRAPHY 
 
5.6.1 VCTE 
In general, liver biopsy provides only a very small part of the whole organ 
and there is a risk that this part might not be representative for the amount 
of liver fibrosis affecting the liver due to heterogeneity in its distribution 
[71]. Besides technical problems, liver biopsy remains a costly and invasive 
procedure that requires physicians and pathologists to be sufficiently 
trained in order to obtain adequate and representative results. Moreover, 
liver biopsy is an invasive procedure, carrying a risk of rare but potentially 
life-threatening complications [72,73]. These limitations have led to the 
development of non-invasive methods for the assessment of liver fibrosis. 
VCTE has been the first method to be employed and has now taken over 
Table 1. Main reported US and Doppler ultrasound signs of portal hypertension in patients with chronic 
liver diseases [66] 
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liver biopsy for the staging and follow up of patients, especially with HCV-
related chronic liver disease. VCTE measurements are performed with an 
ultrasound transducer probe built on the axis of a vibrator by which a 
vibration of mild amplitude and low frequency is transmitted, inducing a 
wave that propagates through the liver tissue (Fig 11). Pulse-echo 
acquisitions are performed to measure the velocity of propagation of the 
wave, which is directly related to tissue stiffness. The volume of the 
analyzed liver is about 100 times greater than that obtained by biopsy, and 
has therefore a potentially lower sampling error. Since fibrosis within the 
liver increases the organ’s stiffness, VCTE has been used to assess the 
presence of fibrosis and cirrhosis and most lately for predicting the 
presence of CSPH. Nevertheless there is conflictual data on the cutoff values 
that indicate the presence of cirrhosis and CSPH. The reasons of these 
discrepancies are likely to be aetiology-driven and related to the 
pathophysiology of PH. The distribution of fibrosis is in fact dependent on 
the underlying cause and the characteristics of the inflammatory process. 
Nodular regeneration ranges from micro to macronodular and this has an 
impact on the distribution and amount of fibrosis between the nodules and 
vascular architectural distortion. Since fibrous tissue is the main 
responsible factor of liver stiffness, the amount but also the topographic 
distribution of fibrosis will influence these values. Hence different liver 
disease aetiologies will have different cutoff values for grading liver 
disease. Although fibrosis is the main drive of increased stiffness, the liver 
is an organ with a distensible but non-elastic envelope (Glisson’s capsule) 
and additional space-occupying tissue abnormalities, such as edema, 
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inflammation, extra-hepatic cholestasis, or congestion, can interfere with 
measurements of LS, independently from fibrosis, by increasing intra-
hepatic pressure. Therefore the results should always be interpreted 
bearing in mind these potential confounding elements [74]. Several studies 
have shown that there is a good correlation between LS values and HVPG in 
patients with advanced liver diseases in both pre- and post-transplant 
settings [75-77]. According to available data, the diagnostic performance of 
VCTE for predicting CSPH (HVPG >10 mmHg) in the setting of patients with 
compensated chronic liver disease/cirrhosis is excellent, with an AUROC of 
0.93 [78]; a 90% sensitivity cut-off for CSPH diagnosis is 13.6 kPa, and a 
90% specific cut-off in this setting is 21 kPa. These cut-offs have been 
shown to allow a correct stratification of presence/absence of CSPH in 
patients with compensated cirrhosis and potentially resectable HCC, thus 
reducing the need for invasive hemodynamic assessment [79]. However, 
while the correlation is excellent for HVPG values between 5 and 10– 12 
mmHg, it hardly reaches statistical significance for values above 12 mmHg 
[Fig 10]  [80-81]. 
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Fig 10. The correlation between liver stiffness and HVPG. Above 10-12 mmHg the correlation 
is lost [81]. 
 
This is because, with the progression of cirrhosis, the mechanisms of PH 
become less dependant on the intra-hepatic resistance to portal flow due to 
tissue fibrosis, and progressively more dependant on extra-hepatic factors  
[82], and since the presence, size and associated risk of bleeding depend on 
high HVPG measurements, LS is not a reliable parameter to monitor or 
predict these endpoints. This observation sets a key limitation to the use of 
LS measurements as a non-invasive surrogate of HVPG beyond the 
prediction of clinically significant (HVPG 10 mmHg) and severe  PH ( HVPG 
≥12 mmHg). Recently, studies employing different technical approaches 
have highlighted the potential usefulness of SS assessment for predicting 
the presence of esophageal varices and the degree of PH in cirrhotic 
patients [83-86]. 
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Fig 11. VTCE: a pulsed vibration is delivered longitudinally through the subcutaneous tissue 
and into the liver for a length of 4 cm X 1 cm. The monitor on the left displays the M-Mode, 
artifacts and the elastogram together with the mean stiffness value and the interquartile 
range (IQR) and IQR/Med. The controlled attenuation parameter (CAP) is also shown on the 
left bottom side of the monitor and is related to the hepatic fat content. 
 
5.6.2 Point Shear Wave Elastography 
The accuracy of ultrasound imaging in diagnosing liver disease has 
increased enormously by giving the possibility to obtain biomechanical 
measurements that reflect the underlying pathophysiological process. LS 
and most lately SS can be measured, providing precious information within 
the same baseline ultrasound assessment. Non-invasive evaluation of liver 
fibrosis has been increasingly used over the last years. Recently, the 
European Federation of Societies for Ultrasound in Medicine and Biology 
(EFSUMB) issued guidelines regarding the clinical application of these 
techniques [87,88]. According to these guidelines, ultrasound-based 
elastographic techniques are classified in: strain techniques and shear 
wave elastography techniques. Three types of elastographic techniques are 
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included in the last category: VCTE (as described above), Point Shear Wave 
Elastography (pSWE) and shear wave elastography (SWE) imaging 
(including 2D-SWE and 3D-SWE). In the pSWE category two techniques are 
included: Acoustic Radiation Force Impulse (ARFI) and ElastPQ (Point 
Quantification). With ARFI, the ultrasound probe produces an acoustic 
“push” pulse that generates shear-waves that propagate into the tissue. 
Their speed, measured in meters/second, is displayed on the screen and 
reflects the underlying tissue stiffness, the propagation speed increasing 
with tissue stiffness. Using image-based localization, shear wave speed may 
be quantified in a precise anatomical area, focused on a region of interest, 
with a predefined size, provided by the system [89,90].  ElastPQ system 
generates an electronic voltage pulse, which is transmitted to the 
transducer. In the transducer, a piezoelectric array converts the electronic 
pulse into an ultrasonic pressure wave. When coupled to the body, the 
pressure wave transmits through body tissues focusing on a specific region 
of interest. The Doppler functions of the system process the Doppler shift 
frequencies from the echoes of moving targets, such as blood, to detect and 
graphically display the Doppler shift of these tissues as flow. The Doppler 
mode creates waves in soft tissues and estimates the tissue stiffness by 
determining the speed at which these shear waves travel. Stiffness 
measurements are expressed both in m/s or in kPa (Fig 12). ARFI 
technique has been validated against VCTE and histology for the staging of 
fibrosis and seems to give better results compared to VCTE in the detection 
and grading of PH. In particular, a good correlation was found between SS 
measurements and the presence and size of varices. More recently real 
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time 2D shear wave elastography (Aixplorer, Supersonic) showed also a 
better correlation with liver fibrosis and the presence of clinically 
significant PH than VCTE [91]. ElastPQ has shown through the years an 
excellent correlation with VCTE for the assessment of different grades of 
liver fibrosis [92]. The integration of ultrasound machines with shear wave 
and point elastography software has clear advantages over VCTE. In the 
latter, the M-mode shown on the monitor helps to detect the homogeneity 
of the underlying liver parenchyma providing guidence for a correct 
measurement acquisition. With pSWE techniques a high definition 
ultrasound image is visualised, allowing the operator to explore the liver 
and gain information on the parenchymal appearance, outline, the presence 
of focal lesions as well as interrogating the portal venous system and 
measuring spleen size. Very small amount of free fluid can also be 
detectable and be highlighted as a first subtle sign of clinical 
decompensation. The measurement of tissue stiffness in addition provides 
an incomparable diagnostic tool which helps to shed light in cases in which 
fibrosis and even cirrhosis can be misdiagnosed because the baseline 
ultrasound findings lack specificity (Fig 13 A, B, C). It also can provide 
valuable information in more complex cases in which the distribution of 
fibrosis is particularly patchy such as PSC (Fig 14) in which the segmental 
distribution of biliary strictures is irregular and can eventually spare the 
right liver lobe, giving the false impression that the liver is either not 
affected or only marginally affected by fibrosis. Ultrasound imaging in this 
case will allow the evaluation of the left lobe and assess its structure (Fig 
15 A and B) highlighting the presence of possible abnormalities. Moreover 
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pSWE can also be used to measure SS, which is particularly important for 
the detection and grading of PH. Nevertheless there is limited data on the 
use of ElastPQ for the assessment of SS, and this technique has not yet been 
validated for the detection, grading and characterisation of CPH and NCPH 
[93]. 
 
 
 
 
 
 
 
Fig 12. ElastPQ (Point Shear Wave Elastography): a small region of interest of 1 cm x 0.5 cm 
is placed on the hepatic parenchyma usually 1-2 cm below the liver capsule in order to 
measure liver stiffness. The shear waves are propagated transversally bypassing the possible 
limitation of narrow intercostal spaces, the presence of free fluid surrounding the liver and 
increased subcutaneous fat. 
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Fig 13 A. Steatotic-looking liver in a patient with mild transaminitis. ElastPQ reveals a normal liver 
stiffness value of 3.99 kPa, excluding the presence of underlying fibrosis. 
 
 
 
 
 
 
            Fig 13 B. Hepatic steatosis with similar appearance. ElastPQ shows a liver stiffness of 10.21 kPa 
compatible with moderate/severe fibrosis. 
 
 
 
 
 
 
 
 
Fig 13 C. Hepatic steatosis with similar B-Mode features to the previous two cases. There is increased 
parenchymal echogenicity in keeping with hepatic steatosis. The echotexture is homogeneous and the 
outline is smooth. However liver stiffness is increased measuring 16.35 kPa, which is compatible with 
cirrhosis. In all three of the above-described cases the baseline ultrasound report highlighted only 
hepatic steatosis. The presence of underlying fibrosis and especially cirrhosis proven on biopsy was 
unsuspectable without an elastography assessment. None of the patients had a significant degree of 
inflammation to justify an increase in stiffness. 
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Fig 14. Non-invasive assessment of liver disease in a patient with PSC. The echotexture is quite 
homogeneous, however the distinctive feature is the presence of well-defined areas of different 
echogenicity scattered throughout the liver (A and B). The hyperechoic areas were proven to correspond 
to areas of reduced biliary drainage secondary to biliary thickening and stricturing on MRCP. ElastPQ was 
used to measure tissue stiffness in the different areas showing that the hypoechoic “dark” areas (C) had a 
stiffness up to 10-15 kPa and the hyperechoic (“bright”) areas (D) were in the range of 50-60 kPa. 
Segmental distribution of fibrosis is typical in PSC. This case demonstrates how these differences can be 
identified and “sampled” with ElastPQ. 
 
 
 
 
 
 
 
A B 
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       Fig 15 A. Two images from an abdominal scan performed in a patient with PSC. The liver has a steatotic 
appearance. The right liver is smooth in outline and has a normal stiffness value (4.22 kPa). The left 
liver lobe is shrunken and the biliary ducts are thickened and dilated. Liver stiffness could not be 
measured in the left lobe because of technical limitations. The patient had a high BMI and in order to 
visualize the left lobe increased subcostal pressure was exerted with the probe which would result in 
over imposed liver stiffness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Fig 15 B. MRCP of the same patient showing in detail the left lobe atrophy with thickening and dilatation 
of the left lobe biliary system. 
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6. SPLEEN IN CHRONIC LIVER DISEASE AND PH  
In order to understand the rationale behind SS measurements and 
interpret the results appropriately, a brief introduction on splenic function, 
structure and relative modifications in this clinical context is mandatory. 
 
6.1  SPLENIC FUNCTION AND STRUCTURE 
The spleen is the largest lymphoid organ of the human body and has the 
fundamental role of filtering the blood eleminating possible microbial 
threats. It has also important hematological and metabolic functions. It 
receives blood from the splenic artery and is drained by the splenic vein 
which together with the superior mesenteric vein constitute the portal 
venous system.  The splenic stroma is constituted by white and red pulp 
and  the marginal zone. The white pulp consists predominantly of 
lymphocytes, together with macrophages and other free cells, lying in a 
specialized reticular meshwork composed of concentric layers of stromal 
cells. In normal conditions three quartes of the volume of the human spleen 
consists of the red pulp, which comprises slender non-anastomosing 
arterial vessels (penicilli), the splenic cords of Billroth, the venous sinuses 
and the pulp veins which drain into the splenic veins and hence are in 
direct communication with the portal vein. The marginal zone is located 
between the white and red pulp and has fundamental immune and 
structural functions. Owing to the communication with the portal venous 
system, in the presence of PH, we can expect an increase in red pulp 
congestion with increased spleen size. 
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6.2  SPLEEN CHARACTERISTICS IN CHRONIC LIVER DISEASE 
 In general, considering the anatomical location of the spleen, an increase in 
portal vascular resistance with consequent reduction in portal blood flow 
should lead to splenic stagnant flow. However, if splenomegaly would only 
be the consequence of congestion due to PH, a relationship between 
splenomegaly and portal pressure would always be expected. Instead, in 
some cases despite the presence of CSPH, no correlation has been found 
between spleen size and portal pressure [94-97] or the degree of 
oesophageal varices [98]. Altogether these data highlight that PH is not the 
only determinant of splenomegaly in cirrhosis and also that PH is not 
always associated to increased spleen size. Histopathological studies have 
demonstrated a clear modification of the splenic architecture in cirrhosis 
with the presence of diffuse tissue fibrosis and neo-angiogenesis [99-102]. 
An increase in the white pulp volume has also been highlighted, with an 
increase in the arterial bed and in peri-arterial lymphatic sheaths [100,103-
105]. The increase in white pulp indicates a pronounced immunologic 
involvement in the genesis of cirrhotic splenomegaly which often can be 
observed for example in patients with PSC, especially when there is an 
association with inflammatory bowel disease. A recent retrospective study 
showed that spleen size differs according to the underlying aetiology of 
liver disease [106] suggesting that the different splenic compartments are 
proportionally involved according to the underlying cause and 
pathophysiological events which differently characterize chronic liver 
disease. Therefore, splenomegaly in cirrhosis cannot be simply classified as 
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congestive, but rather as congestive-hyperplastic without forgetting that 
the inflammatory changes may lead in the long term to the development of 
a intrasplenic fibrotic component (Fig 16). Along these lines a complete 
resolution of cirrhotic splenomegaly after liver transplantation has never 
been reported, probably because of the large irreversibility of the 
structural changes occurring during the long clinical course of cirrhosis. 
Nevertheless, although the size does not show any significant change, post-
transplant measurements reveal a dramatic fall in SS values, suggesting 
that this parameter reflects the congestion of the red pulp which is surely 
expression of the resolution of PH [107].  
 
 
 
 
 
 
 
 
Fig 16 A. Overview of splenic histology (A) in a patient with PSC who 
underwent splenectomy at the time of liver transplantation. 
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         Fig 16 B,C,D,E. The white areas (best seen in B) are the dilated splenic sinusoids which are a consequence of 
splenic congestion secondary to portal hypertension. There is pronounced lymphoid hyperplasia (A and C) 
due to activation of the germinative centres which denotes inflammatory/lymphoid splenic reaction. 
Between the sinusoids there are areas crossed by thickened fibrotic bands as a consequence of a degree of 
splenic fibrosis. In comparison (below) we show a normal spleen from a patient who underwent 
splenectomy because of abdominal trauma. Normal red (D) and white splenic pulp (E). The red pulp is 
compact (the sinusoids are virtual spaces in this section and cannot be distinguished) and the lymphoid 
follicles are small and not activated. The reticulum is so thin that it can barely be noticed.  
      Tu Vinh Luong, Pathology Department – Royal Free Hospital, London 
 
 
 
 
E D 
B C 
49 
 
6.3 SPLENIC-RELATED PARAMETERS IN THE ASSESSMENT OF 
CIRRHOSIS 
The possibility of predicting the presence of oesophageal varices by using 
clinical parameters related to splenomegaly was initially suggested with 
the use of spleen diameter, assessed by ultrasonography, in the platelet 
count/spleen diameter ratio (Plt/Spl) proposed by Giannini et al. [108-
109] and in the score proposed by Kim et al. including also the 
measurement of LS [110]. Along these lines the study by Berzigotti et al. 
proposed risk scores for both CSPH and the presence of oesophageal 
varices, based on the combination of LS, spleen size and platelet count 
[111].  Stefanescu et al [112] and Colecchia et al [113] proposed and the 
latter carried out a study on the measurement of SS measured by VTCE for 
the prediction of esophageal varices in patients with HCV-related cirrhosis.  
All patients also underwent measurement of HVPG and gastroscopy. The 
ability of both SS and LS to predict CSPH and the presence of oesophageal 
varices was compared to the LSPS score, and platelet count to spleen 
diameter score. SS and LS were more accurate than other non-invasive 
parameters in identifying patients with oesophageal varices and different 
degrees of PH. One of the most interesting findings of this study was the 
presence of a strong direct correlation between SS and the whole range of 
HVPG values >5 mm Hg, indicating that the increase in SS progresses 
closely with the progression of PH from the early to the late stages of 
cirrhosis. These results suggest that, in patients with cirrhosis, SS is 
possibly characterized by a wider range of application when compared to 
LS, probably because of a progressively higher relevance of extra-hepatic 
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factors conditioning the increase of portal pressure [80, 114]. These results 
were largely confirmed in a similarly designed study performed in 200 
patients with cirrhosis due to different aetiologies [115]. The possibility of 
expanding these studies by employing an alternative method for the 
measurement of LS and SS, such as ARFI, was suggested by a study where 
both LS and SS were employed for predicting liver fibrosis stage in patients 
with HCV- and HBV-related chronic liver disease [116].  Finally Colecchia 
and co-workers [117] showed that, in compensated cirrhotic patients, a SS 
and MELD predictive model represents an accurate predictor of clinical 
decompensation, with an accuracy at least equivalent to that of HVPG.  
 
7. LIVER BIOPSY AND PH IN CHRONIC LIVER DISEASE 
Liver fibrosis is part of the structural and functional alterations which 
typically characterize chronic liver diseases. It has been described as one of 
the main prognostic factors, as the amount of fibrosis is correlated with the 
development of cirrhosis, PH and liver-related complications. However, 
semiquantiative measurements of liver fibrosis have shown poor 
correlation with the true stage of CLD and hard endpoints such as CSPH, 
hence they cannot be used for prognostication. Moreover, systems such as 
Ishak and Metavir are used to describe viral hepatitis-related fibrosis and 
their employment to quantify/describe fibrosis in other aetiologies is 
inappropriate. Histological systems to sub-classify cirrhosis have been 
used, mainly based on semi-quantitative evaluation of nodular size and 
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septal width [118]. These include proposals by Laennec based on the 
original histological description of cirrhosis [119], by Nagula [120], Kumar 
[121] and Sethasine which showed a good correlation with HVPG [122]. 
Over the last few years computer-aided morphometric measurement of 
collagen proportional area, a partly automated technique, was developed 
and validated providing an accurate and linear evaluation of the amount of 
fibrosis [123]. In fact, quantitative computer-assisted digital-image analysis 
(DIA) of histological liver sections was proven to be a better histological 
index than traditional stage scores correlating with all stages of fibrosis 
and HVPG values in patients with post-transplant HCV infection, moreover 
predcting liver decompensation at 1 year after OLT [124]. More recently 
these results were corroborated by other studies which confirmed that CPA 
is a reliable predictor of the presence of oesophageal varices, hence of 
CSPH (CPA ≥ 14 %) and also of hepatic decompensation (CPA ≥ 18%) 
[125]. In conclusion liver histology, assuming there is no sampling error, 
provides unique diagnostic information particularly for further 
investigating and distinguishing causes of intrahepatic portal hypertension 
which may differ from cirrhosis [55]. In addition morphometric analysis 
measuring CPA should be carried out since it is a true objective 
measurement of the amount of collagen, it faithfully correlates with HVPG 
and has prognostic significance. 
 
 
 
52 
 
8. AIMS AND RESEARCH PLAN 
 
78 patients who were admitted to the Royal Free Hospital and underwent 
haemodynamic assessment with HVPG measurement were prospectively 
recruited in the study in accordance with the following inclusion and 
exclusion criteria. 
 
Inclusion Criteria:  
 patients with chronic liver disease undergoing HVPG measurement.  
 Age > 18  
Exclusion Criteria: 
 Unable to give consent  
 Beta blockers, nitrates and statins 
 
The research study objectives were the following: 
 
1. To evaluate the correlation between VCTE and ElastPQ (pSWE) in a cohort 
of patients with chronic liver disease 
2. To evaluate the correlation of LS  and SS measured by ElastPQ with HVPG 
in patients with chronic liver disease and establish diagnostic cutoffs of SS 
for diagnosing CSPH 
3. To evaluate the correlation between fibrosis grade measured with CPA and 
LS and SS measured by ElastPQ 
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4. To assess the accuracy of LS and SS and their ratio for the characterization 
of PH distinguishing CPH from NCPH. 
 
 
9. PATIENTS AND METHODS 
 
9.1   METHODOLOGY OF INVASIVE AND NON-INVASIVE MEASUREMENT     
OF PH 
After an overnight fast, an abdominal ultrasound scan was carried out 
acquiring both LS and SS with ElastPQ. In a subgroup of patients VCTE 
measurements were also acquired and paired with ElastPQ. An expert 
radiologist or hepatologist, blinded to the elastography results, carried out 
the haemodynamic assessment obtaining the mean value from 3 
consecutive HVPG measurements. HVPG which was classified in different 
grades as follows: grade 0 = HVPG 1-5 mmHg NPH (No PH); grade 1 = HVPG 
6-9 mmHg (NCSPH); grade 2 = HVPG 10-11 mmHg (CSPH); grade 3 = HVPG 
≥ 12 mmHg SPH (Severe PH). 
All patients underwent routine blood tests including full blood count, 
coagulation screen, creatinine, urea, liver function tests (ALT, AST, GGT, 
ALP, bilirubin and serum albumin).  
 
A subgroup of 41 patients had a histological sample taken at the time of the 
HVPG measurement by transjugular approach, percutaneous liver biopsy 
(within a month prior to the haemodynamic assessment) and from the liver 
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specimen obtained from liver resection for those patients who underwent 
surgery to remove the tumour (within a month after the haemodynamic 
assessment).  
The histopathological analysis was carried out performing CPA in order to 
have an objective evaluation of fibrosis and also because CPA is known to 
correlate well with the severity of PH. To corroborate these findings in our 
population we first correlated CPA with different grades of HVPG (Fig 18) 
and then we looked at the correlation of LS and SS using CPA cutoff levels 
for CSPH as previously described (14%). 
Fibrosis scoring systems such as APRI, FIB-4 were compared to both CPA 
and LS measured with ElastPQ. 
A last substudy was finally performed to evaluate the usefulness and 
accuracy of ElastPQ in distinguishing CPH from NCPH in patients with 
EHPVO. Patients were diagnosed as having clinically significant NCPH 
secondary to EHPVO according to radiological (evidence of porto-systemic 
vascular collaterals shown on contrast CT or MRI) criteria. All patients in 
the cirrhotic group had a HVPG ≥ 10 mmHg. 
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9.2 TECHNICAL ASPECTS OF HVPG MEASUREMENT 
Under ultrasound guidance and with local anesthesia a venous introducer 
was placed in the right internal jugular vein by Seldinger technique. Under 
fluoroscopic control and continuous electrocardiographic and arterial 
pressure monitoring, a 7 French balloon-tipped catheter (Medi-Tech 
Boston Scientific Cork, Cork, UK) was guided into the right hepatic vein for 
measurement of WHVP and FHVP. Adequacy of occlusion was checked by 
injection of 5 ml of iodinated radiological contrast medium (Iopamiro 370, 
Bracco, Milan, Italy). Three consecutive readings were taken and the mean 
value acquired as the reference measurement for the diagnosis of portal 
pressure (Fig 17 A, B). 
 
   Fig 17 A. The kit used for HVPG measurement includes local anesthesia, 
normal saline, contrast dye, puncture needle, guide wire, vascular 
introducer, arrow sheath, cobra catheter, Berenstein balloon catheter and 
ultrasound probe to guide the puncture of the internal jugular vein [34]. 
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Fig 17 B. A sequence of fluoroscopic images during HVPG measurement shows 
confirmation of correct location of the catheter in the right hepatic vein. This is done 
by injecting a small amount of contrast with the balloon catheter inflated. The 
contrast will be retained distally to the balloon if the position is correct.  The balloon 
is inflated and a wedge pressure is measure.  Deflating the balloon will allow to 
obtain a free hepatic venous pressure. In the other figure a pressure trace shows the 
corresponding HVPG measurements [34]. 
 
 
9.3 HISTOPATHOLOGY ASSESSMENT: COLLAGEN PROPORTIONATE 
AREA  
Computer-assisted digital image analysis (DIA) of histological sections, 
histochemically stained by the picroSirius red technique, is a method for 
measuring fibrosis morphologically. PicroSirius red staining identifies 
tissue collagen primarily. 
The quantity of bound stain correlates with chemically determined 
collagen content and morphometrically determined hepatic fibrosis. Digital 
image analysis uses segmentation of digital images to measure the area of 
collagen and of tissue, producing a “fibrosis ratio” CPA [124]. 
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Liver histology was obtained either at the same time as HVPG 
measurement by a transjugualr approach, or by percutaneous liver biopsy 
(not more than 3 months from HVPG measurement), or by tissue sampling 
obtained with liver resections for those patients who underwent surgery 
for HCC (within 4 weeks from the haemodynamic assessment). The 
sections of each biopsy stained with PicroSirius red were used for digital 
image analysis (DIA), which was performed by an expert pathologist (A. 
Hall). The equipment setup used consisted of a digital camera (Canon 
Powershot A640 attached to a close-up copystand with backlighting) 
connected to a compatible personal computer.  After whole section digital 
image capture, CPA was measured with Zeiss KS300 image analysis 
software. The CPA measurement included editing steps to eliminate image 
artifacts and structural collagen in large portal tracts and blood vessel 
walls (which do not represent disease-related liver fibrosis). Unfilled 
natural spaces such as vascular cavities were not included in the 
measurements and, because non-collagenous cellular areas such as 
lymphoid aggregates in portal tracts are not stained (red) with picroSirius 
red, these also were not included [118] (Fig 17). 
 
 
 
 
 
 
Fig 18. Histopathology sections of two patients with cirrhosis. No other known method of 
histological analysis was able to distinguish these two samples. CPA was 21% in A and 46% in B. 
The latter was associated to severe portal hypertension and clinical decompensation [119]. 
B 
A 
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9.4  ELASTOGRAPHY ASSESSMENT 
 
9.4.1 ElastPQ 
The elastography measurements were performed using an Affiniti 70 G 
ultrasound system (Philips Healthcare, Bothell, WA, United States) with a 
convex broadband probe C5-1 and ElastPQ® software. As with other shear 
wave elastography methods, Point Shear Wave Elastography is a technique 
in which shear waves are generated inside the liver using radiation force 
from a focused ultrasound beam. The ultrasound machine monitors the 
shear wave propagation using a Doppler-like ultrasound technique, and 
measures the velocity of the shear wave. The shear wave velocity is 
displayed in meters per second (m/s) or in kPa through Young’s modulus E 
= 3 (vS2.ρ), where E is Young’s modulus, vS is the shear wave velocity and ρ 
is the density of the tissue.  
Both liver and spleen measurements were carried out with the patient 
lying supine and with both arms in maximal abduction. The liver was 
imaged and the region of interest was placed 2 cm below the liver capsule, 
in perpendicular position compared to the liver surface and away from 
vessels, ligaments or biliary ducts. A total of 10 measurements were taken 
and median value and standard deviation were acquired. A measurement 
was considered accurate in the presence of a standard deviation lower than 
30% of the median value. Subsequently the spleen was imaged through the 
left intercostal spaces, and keeping the region of interest 1-2 cm below the 
splenic capsule and away from large vessels. The region of interest was 
placed above the splenic hilum at the level of the mid splenic pole. When 
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the spleen was normal in size or not particularly enlarged, or the mid pole 
was not entirely visible, the lower pole was sampled. 10 consecutive 
measurements were taken and median and standard deviation were 
acquired. Both longitudinal diameter and area were also measured. 
 
9.4.2 VCTE 
The patient was positioned supine with the right arm in maximal 
abduction. After having placed a small amount of gel on the tip of the 
transducer, this was placed between the intercostal spaces and 10 
consecutive measurements were acquired. The measurements were 
considered accurate in the presence of an IQR <30% and a success rate 
higher than 60%. Since part of the population undergoing HVPG was 
affected by liver cancer, a preliminary ultrasound scan was always carried 
out before fibroscan measurements to avoid the presence of an underlying 
lesion, or to know if transient elastography was feasible or not because of 
inaccessible healthy liver parenchyma.   
 
10. DATA AND STATISTICAL ANALYSIS 
Statistical analysis was performed by using the Statistical Package for 
Social Science (SPSS), release 20.0 and a p-value <0.05 was considered 
statistically significant. All data were first analysed for normality of 
distribution using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Data 
with normal distribution were expressed as mean ± standard deviation 
(SD); data of skew distribution as median with interquartile rate (IQR), and 
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frequencies as percentages. On the univariate analysis two or more 
population medians were compared using the Mann-Whitney or Kruskal-
Wallis non-parametric U-test, respectively, two or more population means 
using T-Student’s test or ANOVA. The comparison of categorical variables 
was carried out using χ2-test. The correlation of continuous variables was 
assessed with the Pearson’s or Spearman’s correlation coefficient if the 
variables had a normal or non-normal distribution, respectively. A 
multivariate analysis with a binary logistic regression was performed to 
identify predictor factors which were expressed as odds ratio (OR) and 
95% confident interval (CI).  AUROC curves were used to define cut-off 
values. Cross tabs were used to define specificity, sensitivity, negative 
predictive value and positive predictive value. 
 
 
11. RESULTS 
 
11.1 PATIENTS’ CHARACTERISTICS 
78 patients admitted to the Royal Free Hospital between 2015 and 2016 
who underwent haemodynamic assessment with HVPG measurement were 
recruited in this study. 8 patients were excluded because of technical 
difficulties. In 6 of these patients the spleen was too small leading to high 
standard deviation, hence these were considered not reliable and excluded 
from the study. One patient had undergone splenectomy and another had 
large volume ascites and hyperdynamic circulation leading to subtle 
movements of the spleen within the ascitic fluid and inaccurate readings. 
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70 patients (55 male; 15 female) of mixed aetiolgies (NASH, HCV, HBV, ALD 
and Other (HCV/ALD, HBV/ALD, HIV/HBV, NASH/HCV, NASH/ALD, 
PSC/AIH, PBC, AIH, Post OLT/HCV)) were finally enrolled. The population 
characteristics are described in Table 2.  
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TABLE 2: Description of the study population. NASH (non-alcoholic steatohepatitis); HCV (hepatitis C 
virus); HBV (hepatitis B virus); ALD (alcohol liver disease); Combined (mixed aetiologies such as 
HCV/ALD, NASH/HCV HBV/ALD, NASH/ALD, HIV/HBV); Other (Isolated aetiologies such as 
autoimmune hepatitis, primary biliary cirrhosis, post-transplant patients); NPH (No Portal 
Hypertension); NCSPH (non-Clinically significant portal hypertension); CSPH (Clinically significant 
portal hypertension); SPH (Severe Portal Hypertension); HVPG (hepatic venous pressure gradient); 
LpSWE (Liver Point Shear Wave Elastography); SpSWE (Spleen Point Shear Wave Elastography); ALT 
(Alanin Transaminase); AST (Aspartate Transaminase). ALP (Alkaline Phosphatase); APRI (AST to 
platelet ratio score); FIB-4 (Fibrosis 4); MELD (Model for End Stage Liver Disease); LSPS (Liver 
Stiffness*Spleen Diameter/Platelet Count); SSPSA (Spleen Stiffness X Spleen Area/Platelet Count). 
Continuous variables are reported as mean ± standard deviation if the distribution is normal; whereas 
are reported as median (IQR) if they are not normal. 
 
 
 
 
Gender (male/total) 55/70 
Age, (y)                                     60 ± 12 
NASH, n/tot (%) 22/70 (31.4) 
HBV, n/tot (%) 6/70 (8.6) 
HCV,  n/tot (%) 12/70 (17.1) 
ALD,  n/tot (%) 4/70 (5.7) 
OTHER,  n/tot (%) 26/70 (37.2) 
NPH,  n/tot (%) 21/70 (30) 
NCSPH,  n/tot (%) 23/70 (32.9) 
CSPH,  n/tot (%) 8/70 (11.4) 
SPH,  n/tot (%) 18/70 (25.7) 
HVPG, mmHg 8.2 ± 4.8 
LpSWE (kPa) 14.8 (13.2) 
SpSWE (kPa) 40.1 (29.8) 
Spleen Diameter (cm) 13 ± 2.9 
Spleen Area (cm2) 50 (38) 
Platelets 181 ± 88.6 
ALT, UI/l 42.5 (30) 
AST, UI/l 39 (31) 
ALP, UI/l 91 (56) 
Bilirubin, mmol/l 11.50 (12) 
Albumin, mg/dl 41.27 ± 5.8 
INR 1.04 ± 0.2 
Creatinine, mmol/l 72.1 ± 24.5 
APRI 0.7 (0.9) 
FIB-4 2.6 (2.1) 
MELD 7.5 (3) 
LSPS 1.2 (2.2) 
SSPSA 13.1 (25.4) 
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11.2 CONCORDANCE BETWEEN VCTE AND ELASTPQ 
 
45/70 patients had both ElastPQ and fibroscan measurements. We could 
not perform VCTE in every patient because of logistical reasons due to time 
limitation, or because it was not feasible (patients affected by a large lesion 
in the right liver lobe). Of the 45 patients who received both, VCTE was 
performed the same day prior to HVPG in 34/45 patients and in 11/45 
patients the results from a previous fibroscan performed within 3 months 
were used. Biochemical analysis and clinical status in the latter case did not 
show any significant difference. ElastPQ showed an excellent correlation 
with fibroscan (Spearman’s 0.941, p <0.0001) (Fig 19). 
 
 
 
 
Fig 19. 45/70 patients underwent also VCTE  measurement to evaluate its correlation with  
ElastPQ.   A strong correlation was found between the two techniques (Spearman’s 
0.941;p<0,0001). 
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11.3 CORRELATION OF ELASTPQ WITH LIVER FIBROSIS 
 
41/70 patients had an available histological sample that was compared to 
LS measured by pSWE. A significant correlation was seen between CPA and 
each grade of PH (Fig 20). Both liver pSWE (p<0.0001) (Fig 21A) and 
spleen pSWE (p<0.005) (Fig 21B) correlated significantly with CPA. These 
results confirmed once again that CPA reflects the hemodynamic 
modifications of advanced liver disease and, for the first time that LS and SS 
measured by ElastPQ correlate significantly with CPA and, hence with PH 
indirectly measured by the amount of collagen in different categories, and 
independently from liver disease aetiology. Both CPA and LS correlated 
significantly with APRI (p<0.0001) and FIB-4 (p <0.002). 
 
 
 
Fig 20. A strong correlation was observed between CPA and HVPG across all categories of 
portal hypertension (p<0.0001). 
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      Fig 21A. Liver pSWE and CPA  p<0.0001        Fig 21B .  Spleen pSWE and CPA p<0.005                   
 
 
 
 
11.4 DIAGNOSIS AND STAGING OF PH BY ELASTPQ 
 
LS and SS measured by ElastPQ correlated significantly with all categories 
of PH (Fig 22A and 22B). In particular, on univariate analysis liver pSWE, 
spleen pSWE, spleen diameter, spleen area, platelet count, LSPS and a new 
proposed scoring system named SSPSA [Spleen stiffness* (Spleen 
area/platelet count)] (Fig 23-25) as well as APRI, FIB-4 and MELD, all 
correlated significantly with HVPG. A significant correlation was also found 
between PH and bilirubin, ALP, and Albumin. No difference was found 
concerning age, gender, aetiology, AST, ALT and INR (details in Table 3). On 
multivariate analysis SS was the only variable that correlated 
independently with HVPG (OR 1.099; CI 1.017-1.188; p<0.017).  LS and SS 
AUROCs were calculated in order to define relative cutoff values for each 
category of HVPG (Fig 26-28). The most accurate values were obtained for 
SS related to CSPH.  SS AUROC for HVPG≥10 mmHg was 0.918, p<0.0001, 
cut off value 42.7 kPa, sensitivity 96%, specificity 84%, negative predictive 
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value (NPV) 97.4% and positive predictive value (PPV) 78.1%.  Details of 
each category related to both LS and SS are reported in Table 4. 
 
 
 
 
 
 
 
 
 
 
Fig 22A. Liver pSWE correlates significantly across different classes of HVPG. Spleen pSWE 
shows even a better correlation and a more distinct categorization of the different classes as 
shown in the graph on the left and below. 
 
 
Fig 22B. This figure highlights the differences between the correlations of  liver and spleen 
pSWE with HVPG 
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 UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS 
NCPH CSPH p value OR 95% CI p value 
AGE (y) 60.8 58.1 NS    
Gender (male/total) 35/44 20/44 NS    
HCV 5 7 NS    
HBV 5 1 NS    
NASH 16 6 NS    
ALD 2 2 NS    
Other 16 10 NS    
AST 34 41.5 NS    
ALT 45.5 35 NS    
Bilirubin 10.5 15.5 <0.012    
ALP 85.5 110 <0.042    
ALB 43 40 <0.005    
Platelets 204.5 125.5 <0.0001    
INR 1 1 NS    
MELD 7 9 <0.012    
APRI 0.4 1.04 <0.001    
FIB-4 1.8 3.2 <0.0001    
LS (pSWE) 9.8 24 <0.0001    
SS (pSWE) 27.9 55.6 <0.0001 1.099 1.017-1.188 <0.017 
Spleen Size 12.1 14.5 <0.0001    
Spleen Area 44 72.5 <0.0001    
LSPS 0.63 2.99 <0.0001    
SSPSA 6.5 26.5 <0.0001    
 
Table 3. Univariate and multivariate analysis of the study population variables compared to HVPG 
measurement. SS was the only factor independently correlated with HVPG. 
 
 
Fig 23. LSPS which is known to have an excellent correlation with HVPG, being able to 
accurately predict the presence of oesophageal varices, shows a good correlation in our study 
population across different categories of HVPG (p<0.0001).  
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Fig 24.  Spleen pSWE and LSPS are compared in this graph. They both correlate significantly 
with HVPG. However spleen pSWE shows a better and distinct categorization in relation to 
HVPG classes. 
 
 
Fig 25. To further increase the accuracy of SS we proposed a new scoring system which 
included spleen stiffness, spleen area and platelet count (SSPSA). There was a good 
correlation between SSPSA and all categories of HVPG. The correlation was equal. Both had a 
p<0.0001.  However LSPS AUROC was slightly better (see related AUROC graphs). 
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Table 4. Results of the AUROCs for both liver and spleen stiffness for different grades of portal 
hypertension. 
 
 
 
LSWE PORTAL PRESSURE 
 HVPG 6-9 HVPG 10-11 HVPG ≥12 
AUC 95% CI 0.918 (0.851-0.986) 0.895 (0.820-0.970) 0.869 (0.785-0.952) 
Cut-off (kPa) 11.8 18.6 19.9 
Sensitivity (%) 82 85 87 
Specificity (%) 91 84 83 
PPV (%) 81.6 84.6 89 
NPV (%) 91 84.1 83 
SSWE PORTAL PRESSURE 
 HVPG 6-9 HVPG 10-11 HVPG ≥12 
AUC 95% CI 0.898 (0.825-0.971) 0.918 (0.853-0.983) 0.922 (0.861-0.983) 
Cut-off (kPa) 30.2 42.7 50 
Sensitivity (%) 84 96 87 
Specificity (%) 86 84 83 
PPV (%) 83.7 78.1 89 
NPV (%) 85.7 97.4 83 
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Fig 26. AUROC of LSWE, SSWE, LSPS and SSPSA for NCSPH. SSWE 0.898, LSWE 0.918, LSPS 
0.918, SSPSA 0.893. 
 
 
 
 
Fig 27. AUROC of LSWE, SSWE, LSPS and SSPSA for CSPH (SSWE 0.918, LSWE 0.895, LSPS 
0.911, SSPSA 0.895). 
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Fig 28. AUROC of LSWE, SSWE, LSPS and SSPSA for SPH (SSWE 0.922, LSWE 0.869, LSPS 
0.889, SSPSA 0.869). 
 
 
11.5 CHARACTERIZATION OF PH: LS AND SS IN CPH AND NCPH 
 
Finally we carried out a comparison between a subgroup of patients (26) 
with CSPH (HVPG ≥ 10 mmHg) and a population of patients (21) with 
NCPH due to EHPVO. 19/21 had developed PVT secondary to JAK2+ 
related-thrombophilia and 2 patients had developed PVT as a consequence 
of pylephlebitis. Liver pSWE, spleen pSWE, splenic area (SA) and the ratio 
of SS to LS (SS/LS) were all found to have statistically significant 
differences and were able to distinguish the two groups of patients with PH  
(p<0.0001) (Fig 29-32 and Table 5). In particular the median value of LS in 
patients with NCPH was normal (<7 kPa) and the SS was almost twice as 
high as the SS value in cirrhotic patients. Hence the most reliable 
72 
 
parameter to characterize PH is the SS/LS. Figures 33-35 highlight on 
imaging three examples of the differences between the two groups and the 
correlations of LS and SS with HVPG in two cirrhotic patients. 
 CPH NCPH p value 
LSWE (kPa) 24 5.8 <0.0001 
SSWE (kPa) 55.6 93.3 <0.0001 
SA (cm2) 72.4 116 <0.009 
Platelets/mm3 124 180 <0.001 
SS/LS (kPa) 2.3 14.2 <0.0001 
 
         Table 5. Results of comparison between CPH and NCPH. All variables were significantly 
correlated and able to distinguish between the two groups. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
Fig 29.  Liver pSWE in CPH and NCPH (p<0.0001).           Fig 30. Spleen pSWE in CPH and NCPH 
(p<0.0001) 
Fig 31. Spleen Area in CPH and NCPH (p<0.009)                 
  
Fig 32. SS/LS in CPH and NCPH (p<0.0001) 
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Fig 33. Patient with policytemia vera JAK 2 + and portal vein thrombosis. Massive splenomegaly (spleen 
diameter 24.6 cm, spleen area 216 cm2.).  ElastPQ revealed a LS 5.42 kPa and a SS of 176.15 kPa. 
 
 
 
 
 
 
 
 
 
          Fig 34. Patient with HCV/HIV related cirrhosis. The outline is smooth the echotexture is homogeneous. The 
spleen is just slightly enlarged measuring 12.6 cm in diameter. ElastPQ revealed a liver stiffness of 21.25 kPa 
and a spleen stiffness of 50.47 kPa. HVPG was 12 mmHg. 
 
 
 
 
 
 
 
 
Fig 35. Patient with HCV related cirrhosis. The patient had a small lesion in segment VII not shown in these 
images and needed to have preoperative assessment in view of liver resection.   ElastPQ revealed a LS  of 36.7 
kPa.  The spleen was normal in size measuring 9.16 cm in diameter with an area of 33.1 cm2 ,  SS was  44.2 kPa 
and HVPG was 11 mmHg. 
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12.  DISCUSSION 
 
More than 60 years have passed since clinicians started investigating the 
haemodynamic changes of the portal venous system during the course of 
liver disease and other pathologies. The development of new technologies 
has provided useful tools to further understand and manage liver disease. 
The results of this work highlight the practical applications of non-invasive 
assessment following those pathophysiological discoveries.  
 
The first important finding is that liver stiffness measured with ElastPQ had 
an excellent correlation with VCTE (Spearman’s 0.941, p<0.0001) proving 
that despite the heterogeneity of the population in terms of liver disease 
aetiology, ElastPQ was able to reproduce faithfully VCTE results. The 
second finding is the relationship between collagen content and PH. It had 
already been proven that CPA correlates to HVPG but this was shown 
mainly in patients with HCV and patients with recurrent HCV infection and 
rapid progression of liver fibrosis after liver transplantation. Our 
population was composed of 70 patients with different liver disease 
aetiologies and different stages of liver disease. CPA was calculated in 41 
patients with available histopathological samples. Ideally the analysis 
should be carried out in distinct subgroups according to the specific 
aetiologiy but the sample was too small to obtain meaningful results and 
we could not divide the population. Hence the analysis was carried out on 
the whole group with no distinctions. Nevertheless this approach gave 
interesting findings. Although there are known histopathological 
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differences between different aetiologies such as micro and 
macronodularity, and amount of collagen and its distribution, CPA 
correlated very well with each category of HVPG regardless of aetiology. 
Moreover LS measured by ElastPQ showed also a very good correlation 
with CPA, and fibrosis related scoring systems such as APRI and FIB-4. CPA 
is the most reliable histological measurement of liver fibrosis and 
correlates with PH and has prognostic value. Along these lines we showed 
that a correlation, although slightly weaker, exists also between CPA and SS 
highlighting the importance of the latter as a non-invasive parameter with 
prognostic significance related to a non-invasive assessment of fibrosis and 
PH. This interconnection is interesting and important in consideration that 
CPA correlated to HVPG in all different grades and that SS also followed 
CPA accordingly. This finding has never been described previously.  
The results proved the presence of a significant correlation of both LS and 
SS measured by ElastPQ with HVPG across all categories in the whole 
population. The AUROCs showed that for patients with NCSPH (HVPG 6-9 
mmHg) LS had a better AUROC (AUROC 0.918, cutoff 11.8 kPa, PPV 81.6%, 
NPV 91%) compared to SS (AUROC 0.898, cut off 30.2 kPa, PPV 83.7%, NPV 
85.7%). Nevertheless, with the increase of portal pressure the AUROC of LS 
decreased progressively while the accuracy of SS instead increased 
showing the best cutoff for CSPH. The AUROC for SS increased even more 
for the HVPG category of severe portal hypertension but accuracy was 
slightly lower. SS performed better than any other variable and was 
independently correlated to HVPG. This result highlights two important 
findings. First that SS is the best non-invasive parameter to diagnose CSPH. 
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In fact, none of the other parameters including LSPS was able to perform as 
wells as SS. In the attempt to increase further the accuracy of SS a new 
scoring system composed by a combination of SS, spleen area (which we 
believe reflects more faithfully spleen size) and platelet count [spleen 
stiffness*(spleen area/platelet count)] which we named SSPSA was 
proposed. However, although it significantly correlated with all HVPG 
categories (p<0.0001) it lost its significance on multivariate analysis and 
had a lower AUROC compared to SS alone. We believe that the reason for 
this result is to be found in the discrepancy between spleen size and PH. 
While for NCSPH we obviously expect to find normal sized spleens (in liver 
disease) we assume in theory to see a proportional increase in size 
following the raise in portal pressure. However, although spleen diameter 
and area both showed a very good correlation on univariate analysis 
(p<0.0001) a very high standard deviation was found in patients with CSPH 
and SPH meaning that this population of patients regardless of the severity 
of PH could be found to have a very large spleen but also a relatively small 
one. In view of optimising non-invasive assessment of liver disease this 
finding is of crucial importance since spleen size and any scoring system 
that includes it, potentially will reduce their accuracy especially in the 
presence of CSPH. In fact, it is possible that one of the reasons of this 
finding is the variety of aetiologies from which our population is composed. 
As previously mentioned spleen size in cirrhosis is influenced by the 
underlying aetiology [107]. However, if this finding raises an argument on 
the accuracy and usefulness of spleen size as a “marker” of PH, on the other 
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hand it strengthens even more the usefulness of SS which was shown to be 
independently correlated to PH regardless of splenic size. 
Previous studies showed that LSPS is an excellent predictor of CSPH. 
Nevertheless, it was used in populations composed by HCV-related 
cirrhosis where probably a linear correlation is found between PH and 
splenic size. The results of this study reveal that in the presence of a 
heterogeneous population with different aetiologies SS performs better 
than LSPS. 
Finally the results showed that LS and SS can be used during the same 
ultrasound examination to distinguish CPH from NCPH and therefore 
characterise PH. The liver and spleen are coupled organs due to their 
communication through the portal venous system. This link is particularly 
obvious in cirrhosis in which the increased intrahepatic resistance reflects 
through the portal venous system on splenic congestion and the 
development of collateral vascular circulation. In this clinical scenario LS is 
typically increased owing to advanced fibrosis and SS is increased 
accordingly for the above-mentioned reasons reflecting the severity of PH. 
In NCPH due to EHPVO there is a disconnection between these two organs. 
Liver parenchyma is typically not affected or marginally affected since it 
never develops significant fibrosis and stiffness is usually normal or 
slightly increased unless there are other confounding pathophysiological 
factors (e.g cholestasis due to choledocical varices, involvement of hepatic 
veins in overlap Budd Chiari Syndrome, nodular regenerative hyperplasia 
in patients with haematological disorders). The spleen instead is typically 
increased in size and extremely stiff (Fig 34). It is of note that the majority 
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of patients in our population of NCPH were affected by MPN in which the 
spleen is often involved and this probably reflects also the underlying 
splenic infiltration. Nevertheless all these patients had CSPH complicated 
by the development of large varices as shown on CECT; and the two 
patients with PVT secondary to pylephlebitis had similar features in terms 
of LS and SS measurements. Platelet count was normal in all patients with 
NCPH representing a distinctive feature compared to the low platelet count 
of patients with CSPH due to cirrhosis. It should be highlighted that the 
population of this substudy does not include cases of IPH in which often 
splenomegaly is observed, spleen stiffness is high in the presence of CSPH 
and liver stiffness can be slightly/moderately increased but without 
reaching the values found in cirrhosis. Platelet count is usually low as a 
consequence of hypersplenism. 
Finally it needs to be remarked that SS might be relatively low in the 
presence of PH complicated by large vascular shunts which decongest the 
portal venous system and in the presence of iatrogenic shunts such as 
TIPSS. It might be slightly increased, but not to the extent seen in the 
presence of CSPH, in patients with lymphoproliferative disorders or 
splenomegaly secondary to increased lymphoid hyperplasia which can be 
observed in patients with PSC and underlying Inflammatory bowel disease.  
In summary our study shows that liver and spleen stiffness measured by 
ElastPQ is an excellent method to assess liver disease. It provides rapid and 
accurate information on the amount of fibrosis and severity of PH which 
could be particularly useful before endoscopic screening for oesophageal 
varices or in the pre-assessment for patients who are in the need to 
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undergo liver resection for HCC. Particularly regarding variceal screening, 
although Baveno Consensus recently provided general guidence on the 
cutoff values for predicting the presence/absence of oesophageal varices, 
the aetiology of liver disease evaluated regarding those values was mainly 
virus-related. Although the sample population of this study is relatively 
small, it was shown that SS has the potential to provide better prognostic 
information compared to LS since it is more influenced by extrahepatic 
factors, which are involved in more advanced stages of liver disease. In 
addition it is less influenced by aetiology, liver inflammation, cholestasis 
and is truly a more reliable expression and surrogate marker of PH.  
Nevertheless it is the overal evaluation of the coupling of liver and spleen 
that provides the most useful information for the understanding of liver 
disease and the presence and characterisation of PH. 
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